Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | HTR2B | P41595 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096119 | 0.92 | HTR2C (0.50) | MTNR1BHTR2CHTR2BHTR2AESR1 | |
| SCHEMBL4936392 | 0.86 | HTR2C (0.48) | MTNR1BHTR2CHTR2BHTR2AESR1 | |
| SCHEMBL1094838 | 0.86 | HTR2C (0.48) | MTNR1BHTR2CHTR2BHTR2AESR1 | |
| SCHEMBL4936397 | 0.86 | HTR2C (0.48) | MTNR1BHTR2CHTR2BHTR2AESR1 | |
| SCHEMBL1095374 | 0.84 | HTR2C (0.51) | MTNR1BHTR2CHTR2BHTR2AESR1 | |
| SCHEMBL1095441 | 0.83 | ESR1 (0.42) | MTNR1BHTR2CHTR2BHTR2AESR1 | |
| SCHEMBL1095121 | 0.81 | ESR1 (0.61) | MTNR1BESR1ESR2MTNR1ALMNA | |
| SCHEMBL1094747 | 0.79 | MTNR1B (0.43) | MTNR1BHTR2CHTR2BHTR2AESR1 | |
| SCHEMBL16417004 | 0.77 | ESR1 (0.62) | ESR1ESR2KMT2AMEN1 | |
| SCHEMBL15194348 | 0.77 | HTR2A (0.47) | MTNR1BHTR2CHTR2AESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374796-B1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes | ARENA PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8993750-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | ARENA PHARMACEUTICALS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8846906-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8575149-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8546379-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546378-B2 | 5HT2C receptor modulator compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-7514422-B2 | 5HT2c receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1833473-A2 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | ARENA PHARMACEUTICALS, A DELAWARE CORPORATION | 2007-03-15 | — | — | US | disclosed |
| EP-1411881-B9 | 5HT2C RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006071740-A2 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| US-6953787-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| EP-1557409-A1 | 5HT2C receptor modulators | Arena Pharmaceuticals, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1411881-B1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| US-20030225057-A1 | 3-Benzoazepine derivatives | ARENA PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225057-A1 | 3-Benzoazepine derivatives | HTR2C, HTR1A, HTR3A | MTNR1B 46/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | HTR2C, HTR3C, HTR3B | MTNR1B 43/4885HTR2C 1/4885HTR2B 14/4885 |
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | HTR2C, HTR3B, HTR3C | MTNR1B 37/4885HTR2C 1/4885HTR2B 6/4885 |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | HTR2C, HTR2A, HTR5A | MTNR1B 55/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | MTNR1B 42/4885HTR2C 1/4885HTR2B 7/4885 |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | MTNR1B 42/4885HTR2C 1/4885HTR2B 7/4885 |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | MTNR1B 42/4885HTR2C 1/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.